|
1
|
Quach H, Ritchie D, Stewart AK, Neeson P,
Harrison S, Smyth MJ and Prince HM: Mechanism of action of
immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia.
24:22–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lonial S, Dimopoulos M, Palumbo A, White
D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV,
Magen H, et al: Elotuzumab therapy for relapsed or refractory
multiple myeloma. N Eng J Med. 373:621–631. 2015. View Article : Google Scholar
|
|
3
|
Dimopoulos MA, Oriol A, Nahi H, San-Miguel
J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki
K, et al: Daratumumab, lenalidomide and dexamethasone for multiple
myeloma. N Eng J Med. 375:1319–1331. 2016. View Article : Google Scholar
|
|
4
|
Lonial S, Durie B, Palumbo A and
San-Miguel J: Monoclonal antibodies in the treatment of multiple
myeloma: Current status and future perspectives. Leukemia.
30:526–535. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito T, Ando H, Suzuki T, Ogura T, Hotta K,
Imamura Y, Yamaguchi Y and Handa H: Identification of a primary
target of thalidomide teratogenicity. Science. 327:1345–1350. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lopez-Girona A, Mendy D, Ito T, Miller K,
Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, et
al: Cereblon is a direct protein target for immunomodulatory and
antiproliferative activities of lenalidomide and pomalidomide.
Leukemia. 26:2326–2335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fischer ES, Bohm K, Lydeard JR, Yang H,
Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM,
et al: Structure of the DDB1-CRBN E3 ubiquitin ligase in complex
with thalidomide. Nature. 512:49–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kronke J, Udeshi ND, Narla A, Grauman P,
Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, et al:
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in
multiple myeloma cells. Science. 343:301–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chakraborty R, Muchtar E, Kumar S, Buadi
FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy
MQ, et al: The impact of induction regimen on transplant outcome in
newly diagnosed multiple myeloma in the era of novel agents. Bone
Marrow Transplant. 52:34–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Durie BG, Hoering A, Abidi MH, Rajkumar
SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R,
et al: Bortezomib with lenalidomide and dexamethasone versus
lenalidomide and dexamethasone alone in patients with newly
diagnosed myeloma without intent for immediate autologous stem-cell
transplant (SWOG S0777): A randomised, open-label, phase 3 trial.
Lancet. 389:519–527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi CX, Kortum KM, Zhu YX, Jedlowski P,
Bruins L, Braggio E and Stewart AK: Proteasome inhibitors block
Ikaros degradation by lenalidomide in multiple myeloma.
Haematologica. 100:e315–e317. 2015.PubMed/NCBI
|
|
12
|
Chapman MA, Lawrence MS, Keats JJ,
Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann
GJ, Adli M, et al: Initial genome sequencing and analysis of
multiple myeloma. Nature. 471:467–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spencer A, Yoon SS, Harrison SJ, Morris
SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB and Chen
C: The novel AKT inhibitor afuresertib shows favorable safety,
pharmacokinetics and clinical activity in multiple myeloma. Blood.
124:2190–2195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Narita T, Ri M, Masaki A, Mori F, Ito A,
Kusumoto S, Ishida T, Komatsu H and Iida S: Lower expression of
activating transcription factors 3 and 4 correlates with shorter
progression-free survival in multiple myeloma patients receiving
bortezomib plus dexamethasone therapy. Blood Cancer J. 5:e3732015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ri M, Tashiro E, Oikawa D, Shinjo S,
Tokuda M, Yokouchi Y, Narita T, Masaki A, Ito A, Ding J, et al:
Identification of Toyocamycin, an agent cytotoxic for multiple
myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA
splicing. Blood Cancer J. 2:e792012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dumble M, Crouthamel MC, Zhang SY, Schaber
M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA,
et al: Discovery of novel AKT inhibitors with enhanced anti-tumor
effects in combination with the MEK inhibitor. PLoS One.
9:e1008802014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Munugalavadla V, Mariathasan S, Slaga D,
Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, et
al: The PI3K inhibitor GDC-0941 combines with existing clinical
regimens for superior activity in multiple myeloma. Oncogene.
33:316–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Pal R, Monaghan SA, Schafer P,
Ouyang H, Mapara M, Galson DL and Lentzsch S: IMiD immunomodulatory
compounds block C/EBP{beta} translation through eIF4E
down-regulation resulting in inhibition of MM. Blood.
117:5157–5165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han EK, Leverson JD, McGonigal T, Shah OJ,
Woods KW, Hunter T, Giranda VL and Luo Y: Akt inhibitor A-443654
induces rapid Akt Ser-473 phosphorylation independent of mTORC1
inhibition. Oncogene. 26:5655–5661. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhodes N, Heerding DA, Duckett DR,
Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang
SY, Robell K, et al: Characterization of an Akt kinase inhibitor
with potent pharmacodynamic and antitumor activity. Cancer Res.
68:2366–2374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaji M, Ota A, Wahiduzzaman M, Karnan S,
Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y and Haniuda M: Novel
ATP-competitive Akt inhibitor afuresertib suppresses the
proliferation of malignant pleural mesothelioma cells. Cancer Med.
6:2646–2659. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Richter JD and Sonenberg N: Regulation of
cap-dependent translation by eIF4E inhibitory proteins. Nature.
433:477–480. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alkhatib A, Werner M, Hug E, Herzog S,
Eschbach C, Faraidun H, Köhler F, Wossning T and Jumaa H: FoxO1
induces Ikaros splicing to promote immunoglobulin gene
recombination. J Exp Med. 209:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu Z and Tindall DJ: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raje N, Kumar S, Hideshima T, Ishitsuka K,
Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi
NC, et al: Combination of the mTOR inhibitor rapamycin and CC-5013
has synergistic activity in multiple myeloma. Blood. 104:4188–4193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Y, He X, Sui Y, Yu R and Xu G:
Transcription factor IKZF1 is degraded during the apoptosis of
multiple myeloma cells induced by kinase inhibition. FEBS Lett.
589:2233–2240. 2015. View Article : Google Scholar : PubMed/NCBI
|
